King Khaled Eye Specialist Hospital   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Riyadh Saudi Arabia (1979)

Organization Overview

First Clinical Trial
2005
NCT00238862
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Fowzan Alkuraya | J. Fernando Arevalo, MD FACS | King Khaled University Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

bevacizumab (avastin) (2 trials)

Drugs in Phase 3 Trials (3)

mycophenolate (CellCept) (1 trial)

naltrexone (revia) (1 trial)

prednisone (meticorten) (1 trial)

Drugs in Phase 2 Trials (1)

COVID-19 convalescent plasma (1 trial)

Drugs in Phase 1 Trials (1)

adeno-associated virus (1 trial)

Drugs in Other Trials (5)

amniotic membrane (1 trial)

autologous serum (1 trial)

midazolam (versed) (1 trial)

ondansetron (zofran) (1 trial)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 4)

Dissociative Disorders (Phase 3)

Edema (Phase 4)

Macular Edema (Phase 4)

Neoplasm Metastasis (Phase 3)

Retinal Detachment (Phase 3)

Retinal Diseases (Phase 4)

Uveitis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 11